Reduced expression of TGFB1, a ligand for the TGFß signaling pathway, was linked to retinoic acid therapy resistance in MYCN amplified cell lines [101], whereas TGFB1 upregulation in primary NB patients without MYCN amplification was associated with worse clinical outcome [102]. This evidence concerns the gene MYCN and neuroblastoma.